IMMUNOHISTOCHEMICAL BIOMARKERS IN EC 119 5 Table 2. Univariate and multivariate Cox regression analysis of RFS Variable Univariate RFS Multivariate RFS HR 95% CI P-value HR 95% CI P-value ESMO-ESGO-ESTRO risk classification ‘Low - Intermediate - High-intermediate’ vs ‘High – Advanced/metastatic’ 3.92 2.52-6.08 <0.001* 3.11 1.93-5.02 <0.001* Immunohistochemical markers p53-abnormal 2.94 1.83-4.72 <0.001* 1.58 0.92-2.71 0.097 L1CAM+ 4.27 2.63-6.92 <0.001* 1.78 0.98-3.21 0.058 ER/PR- 3.16 2.03-4.91 <0.001* 1.54 0.90-2.63 0.115 Abbreviations: CI, confidence interval; ER/PR, estrogen receptor/progesterone receptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology-European SocieTy for Radiotherapy & Oncology-European Society of Gynaecological Oncology ; HR, Hazard ratio; L1CAM, L1 cell-adhesion molecule; RFS, Recurrence-free survival. * p<0.05 Table 3. Univariate and multivariate Cox regression analysis of DSS Variable Univariate DSS Multivariate DSS HR 95% CI P-value HR 95% CI P-value ESMO-ESGO-ESTRO risk classification Low - Intermediate - High-intermediate’ vs ‘High – Advanced/metastatic’ 6.93 3.82-12.57 <0.001* 5.69 3.03-10.67 <0.001* Immunohistochemical markers p53-abnormal 4.44 2.56-7.69 <0.001* 1.88 1.00-3.51 0.048* L1CAM + 5.43 3.19-9.26 <0.001* 1.17 0.59-2.31 0.656 ER/PR- 5.49 3.30-9.12 <0.001* 2.74 1.48-5.07 0.001* Abbreviations: CI, confidence interval; DSS, disease-specific survival; ER/PR, estrogen receptor/progesterone receptor; ESMO-ESGO-ESTRO, European Society for Medical Oncology-European SocieTy for Radiotherapy & Oncology-European Society of Gynaecological Oncology ; HR, Hazard ratio; L1CAM, L1 cell-adhesion molecule. * p<0.05 Immunohistochemical expression in relation to lymph node status The LN status in relation to abnormal IHC expression (p53-abn, L1CAM+ or ER/PR-) is shown in Supplementary Figure S3. LNM was observed in 21.4% of p53-abn, 31.3% of L1CAM+, and 20% of ER/PR- cases. Survival outcome curves (RFS and DSS) of abnormal and normal IHC expression in relation to LN status (N1/N0) is shown in Supplementary Figure S4 A-C and S5 A-C. Patients with LNM (N1) and p53-abn or L1CAM+ had significantly decreased RFS/DSS compared to patients having LNM (N1) and normal IHC expression (p53-wt or L1CAM-), or patients without LNM (N0) and normal/abnormal IHC expression (p<0.001). No significant reduction in RFS was seen in patients with LNM (N1) and ER/PR- compared with patients having LNM (N1) and ER/PR+ (Supplementary Figure
RkJQdWJsaXNoZXIy MTk4NDMw